Japan Post-Marketing Surveillance for Peficitinib to Assess Safety &

Clinical Trial Description

This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP). ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT05047341` - A Study of Human Substance Balance and Biotransformation of [14C]SHR0302	Phase 1
Withdrawn	`NCT02786563` - Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Completed	`NCT03257852` - A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	Phase 2
Completed	`NCT03660059` - A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	Phase 3
Not yet recruiting	`NCT05486715` - Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
Completed	`NCT03682705` - A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis	Phase 2
Active, not recruiting	`NCT04574492` - A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Active, not recruiting	`NCT02805010` - Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	Phase 1
Completed	`NCT01871961` - Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient	Phase 1
Completed	`NCT04497597` - A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Terminated	`NCT02775656` - UCB Cimzia Pregnancy Follow-up Study
Completed	`NCT01173120` - Methotrexate - Inadequate Response Device Sub-Study	Phase 3
Completed	`NCT03223012` - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Completed	`NCT03086343` - A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs	Phase 3
Terminated	`NCT01569152` - Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)	Phase 2
Completed	`NCT02105129` - A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	Phase 1
Completed	`NCT01577563` - Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).	N/A
Completed	`NCT01618955` - Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device	Phase 2
Completed	`NCT01618968` - Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device	Phase 2
Completed	`NCT03339089` - Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

NCT number	NCT03971253
Study type	Observational
Source	Astellas Pharma Inc
Contact	Astellas Pharma Inc.
Email	astellas.registration@astellas.com
Status	Recruiting
Phase
Start date	September 2, 2019
Completion date	December 31, 2025

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms